9. February 2010 00:17
People with anorexia nervosa, paradoxically, have strikingly high levels of fat within their bone marrow, report researchers at Children's Hospital Boston. Their findings, based on MRI imaging of the knees of 20 girls with anorexia and 20 healthy girls of the same age, appear in the February issue of the Journal of Bone and Mineral Research.
[More]
5. February 2010 08:18
Gentium S.p.A. today announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicentre study," has been awarded the Van Bekkum Award for the best abstract submitted to the physician's program for the European Group for Blood and Marrow Transplantation's (EBMT) 36th Annual Meeting, to be held in Vienna, March 21-24, 2010.
[More]
5. February 2010 05:52
CORD:USE Cord Blood Bank and its program at South Miami Hospital are being featured on CNN en Espanol's show "Salud." This story on the importance of cord blood donation aired this week and can be seen Friday, February 5 at 9:30 a.m. EST and Sunday, February 7 at 9 a.m. EST and 3 p.m. EST on CNN en Espanol.
[More]
d42e96ff-55e9-41bf-8724-86d744fb4325|0|.0
Posted in: Healthcare News
Tags: Anemia, Blood Donation, Bone, Bone Marrow, Cell, Hospital, Leukemia, Lymphoma, Placenta, Sickle Cell Anemia, Stem Cell, Thalassemia, Transplant
5. February 2010 00:54
Bioheart, Inc., announced today that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Bioheart’s MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells,that are grown from a patient’s own muscle. MyoCell® has been tested successfully on patients in four clinical trials.
[More]
7ada3afa-07af-445f-9de0-0569a40588f6|0|.0
Posted in: Device / Technology News | Medical Science News | Medical Condition News
Tags: Adenovirus, Angiogenesis, Arrhythmia, Biopsy, Biotechnology, Blood Vessel, Bone, Bone Marrow, Cardiovascular Disease, Catheter, Cell, Congestive Heart Failure, Heart Failure, Hospital, Intensive Care, Stem Cell, Viral Vector
5. February 2010 00:42
Protalix Biotherapeutics, Inc. today announced that data from its pivotal Phase III trial of taliglucerase alfa in patients with Gaucher disease will be presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010, February 10-12, 2010 in Miami, Florida.
[More]
5. February 2010 00:33
ThermoGenesis Corp., a leading supplier of innovative products for processing and storing adult stem cells, today announced a new enhanced distribution agreement with GE Healthcare, a unit of General Electric Company, for its AXP® AutoXpress ™ (AXP) System used in the processing of cord blood.
[More]
4. February 2010 02:59
Although obesity is a risk factor for diabetes and coronary heart disease worldwide, only some obese individuals go on to develop these metabolic complications, while others are relatively protected. Defining these protective factors could help scientists prevent disease in the wider population.
[More]
aa1a5403-63ab-4a2d-9777-b9445934370b|0|.0
Posted in: Medical Science News | Medical Condition News
Tags: Biochemistry, Bone, Bone Marrow, Cardiovascular Disease, Coronary Heart Disease, Cytokines, Diabetes, Diet, Immunology, Insulin, Insulin Resistance, Neurological Disease, Obesity
4. February 2010 02:07
Shire plc, the global specialty biopharmaceutical company, today announced that data from one of three Phase III clinical trials for velaglucerase alfa, the company's enzyme replacement therapy (ERT) in development for the treatment of Type 1 Gaucher disease, will be presented at the Lysosomal Disease Network (LDN) World Symposium, February 10-12, 2010 in Miami, Florida.
[More]
acf0c455-4940-46cf-88c3-a794ac09f13c|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Amino Acid, Anemia, Bone, Bone Marrow, Cardiomyopathy, Cell, Hearing Loss, Leukodystrophy, Myelin, Prescription Drug, Renal Failure, Stroke, Thrombocytopenia, Velaglucerase alfa
3. February 2010 04:32
Medical researchers were shocked to discover that virtually all human embryonic stem cell lines being used in 2005 were contaminated. Animal byproducts used to line Petri dishes had left traces on the human cells. If those cells had been implanted in a human body they likely would have been rejected by the patient's immune system.
[More]
3. February 2010 04:16
Arrowhead Research Corporation today announced publication in Proceedings of the National Academy of Sciences (PNAS) of a study using Nanotope’s lead compound for cartilage regeneration. The study’s authors, which include Nanotope co-founder Dr. Samuel Stupp, showed that Nanotope’s bioactive nanofiber system promotes the growth of new cartilage in a rabbit model. The treatment is engineered to repair cartilage defects by working with an animal’s own bone marrow stem cells to stimulate the production of new natural cartilage.
[More]
3. February 2010 04:06
Arrowhead Research Corporation has announced publication in Proceedings of the National Academy of Sciences (PNAS) of a study using Nanotope's lead compound for cartilage regeneration.
[More]
3. February 2010 03:46
Banner Health is expanding its relationship with the Premier healthcare alliance to include Premier’s OperationsAdvisor® (OA) Web-based labor benchmarking solution.
[More]
2. February 2010 23:35
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing Teva’s Biologics License Application (BLA) for XM02, a granulocyte colony-stimulating factor (G-CSF) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.
[More]
2. February 2010 06:45
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO’s official communication that the Company’s application has successfully completed examination and that a patent will be issued.
[More]
361207b9-1e4c-43fa-8270-8369821eba8e|0|.0
Posted in: Medical Patent News | Pharmaceutical News
Tags: Bone, Bone Marrow, Cancer, Cell, Chemotherapy, Dendritic Cell, Immunology, Oncology, Radiotherapy, Stem Cell, Transplant
2. February 2010 06:11
Protalix BioTherapeutics, Inc. announced today that, in connection with the New Drug Application (NDA) filed by the Company in December 2009 for taliglucerase alfa for the treatment of Gaucher disease, the U.S. Food and Drug Administration (FDA) has requested additional data regarding the Chemistry, Manufacturing and Controls (CMC) section of the NDA.
[More] 
Subscribe